ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS

BACKGROUND: Clinical benefit of continuing bevacizumab beyond progression is unknown in glioblastomas. A biomarker analysis of the AVAglio trial suggested that proneural subtype of IDH-wildtype glioblastoma patients may receive an OS benefit from a first-line bevacizumab. This study explored biomark...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: Ichimura, Koichi, Nagane, Motoo, Kato, Mamoru, Narita, Yoshitaka, Aoki, Tomokazu, Tanaka, Shota, Mukasa, Akitake, Wakabayashi, Toshihiko, Uzuka, Takeo, Nakamura, Hideo, Arakawa, Yoshiki, Suehiro, Satoshi, Nakada, Mitsutoshi, Kitahara, Mai, Hibiya, Yuko, Narushima, Daichi, Onuki, Ritsuko, Morita, Satoshi, Nishikawa, Ryo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2019
Onderwerpen:
Adult Clinical Trials - Non-Immunologic
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846955/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.048
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items